Tizanidine Tablet
Product Images NDC 72789-327

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 72789-327). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (72789327)

The packaging label for Tizanidine USP 4 mg tablets by PD-Rx Pharmaceuticals, Inc. The label indicates a 20-tablet package with NDC 72789-327-20, includes warnings about drowsiness, dosage instructions, lot number G23B99, and expiration date 10/2025. It states tablets are not interchangeable with capsules and highlights prescription-only status.*

FDA Label Image

Tizanidine-1 (Tizanidine 1)

Chemical structure diagram of the active ingredient Tizanidine hydrochloride, showing its molecular arrangement with a chlorine-substituted benzene ring fused to a thiadiazole ring and linked to an imidazoline group.*

FDA Label Image

Tizanidine-2 (Tizanidine 2)

A line graph showing plasma concentration of Tizanidine (ng/ml) over time in hours from dosing. Four data series compare 2x 4 mg Tizanidine tablets and capsules, taken with and without food, showing peak plasma levels and elimination patterns over 24 hours.*

FDA Label Image

Tizanidine-3 (Tizanidine 3)

A line graph comparing the improvement in Ashworth Score over time post-dose for three groups: 16 mg tizanidine, 8 mg tizanidine, and placebo. The x-axis represents hours post-dose from 0 to 6, and the y-axis shows improvement in Ashworth Score, ranging from -5 to 0. Data points include error bars indicating variability.*

FDA Label Image

Tizanidine-4 (Tizanidine 4)

A line chart depicting improvement in Ashworth Score over three time points: End of Titration (Study Week 3), End of Maintenance (Study Week 7), and Endpoint (Last Observation Carried Forward). The chart compares two groups: tizanidine (mean dose 28.8 mg) showing negative improvement scores, and placebo showing scores near zero or positive, with error bars indicating variability.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.